Vetanco

What Vetanco does

Vetanco is a privately held multinational veterinary pharmaceutical laboratory founded in 1987 and headquartered in Vicente López, Buenos Aires, Argentina. The company researches, develops, manufactures, and commercializes veterinary products focused on animal health and production for the food animal industry, primarily serving poultry, swine, and cattle producers across Latin America and select international markets. Its portfolio of 200+ products spans biologicals (recombinant subunit vaccines such as vedevax BLOCK, Biotech Vac Salmonella, and IgY antibody products like Bioinnovo IgY DNT), metabolic regulators, probiotics (Floramax B-11, Zymospore), phytogenic additives (Herbanoplex CP), anticoccidials, mycotoxin control solutions (Detoxa Plus, Inactivator), and complementary digital tools including the VIIP intestinal integrity program and Vetancid mobile applications.

The business operates through a multi-channel GTM model combining direct sales via seven wholly-owned subsidiaries (Argentina, Brazil, Mexico, Colombia, Uruguay, Panama, USA) with an extensive distributor network covering 40+ countries. Manufacturing is anchored at the 33,000 m² GMP-certified plant in General Rodríguez, Argentina, supplemented by contract manufacturing for third-party multinationals. Two jointly-controlled joint ventures drive innovation: BV Science (with Hungary's Dr. Bata Ltd., formed 2016) for antibiotic-free solutions across the Americas, Europe, and Asia; and Bioinnovo S.A. (with Argentina's INTA research institute) for biotechnology products. The company derives revenue primarily from one-time sales of veterinary pharmaceutical products, biologicals, and feed additives, with B2B pricing conducted on a quote basis. The company holds 600+ product registrations globally and has been recognized with Argentine export and GMP certifications.

Vetanco employs 500+ staff with strong scientific credentials, including R&D leadership from USDA-ARS and CONICET. The company maintains a regional mycotoxin prevalence database of 32,000+ samples across 10 Latin American countries and publishes annual technical references (e-Book de Micotoxinas, Detoxa Book) that establish industry standard reference content in the region. Named customers include Jamaica Broilers Group and Hy-Line Latin America, though the customer base spans thousands of enterprise producers across multiple species and geographies, with no single customer concentration disclosed.

Name

Vetanco

Legal name

Vetanco S.A.

Website

https://vetanco.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

251–500 employees

Short description

Vetanco is a privately held Argentine-founded veterinary pharmaceutical laboratory that develops, manufactures, and commercializes vaccines, feed additives, and biologicals for poultry, swine, and cattle producers across 40+ countries, serving enterprise food animal operations through direct subsidiaries and distributors.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals and Animal Health

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Veterinary biological vaccines
• Animal feed additives
• Mycotoxin control solutions

Headquarters

HQ city

Vicente López

HQ country

Argentina

HQ region

Latin America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Veterinary Pharmaceutical Products: Sale of veterinary medications including antibiotics, anti-parasitics, metabolic regulators for production animals (poultry, swine, cattle) and companion animals
2. Biological Products (Vaccines): Sale of biological products including recombinant vaccines (vedevax BLOCK, Biotech Vac Salmonella) and IgY antibody products (Bioinnovo IgY DNT)
3. Feed Additives: Sale of additives including probiotics, phytogenic compounds, mycotoxin controllers, and premixes for animal feed
4. Contract Manufacturing: Manufacturing of products for other multinational companies using GMP-certified facilities

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Vetanco researches, develops, manufactures, and commercializes more than 200 veterinary pharmaceutical and biological products for food animal production (poultry, swine, cattle) and companion animals. The portfolio spans vaccines (recombinant subunit and IgY antibody biologicals), antibiotics, anti-parasitics, metabolic regulators, probiotics, phytogenic additives, mycotoxin controllers, coccidiostats, and disinfectants, complemented by digital monitoring tools (VIIP, Vetancid App). Products are sold through subsidiaries and a distributor network across 40+ countries, with 600+ product registrations and contract manufacturing services for other multinationals.

Product overview

Vetanco is a multinational veterinary pharmaceutical company that develops, manufactures, and commercializes products for animal health and production since 1987. The company operates a unified product portfolio organized across multiple categories: Biologicals (BIOTECH VAC SALMONELLA, vedevax BLOCK, Bioinnovo IgY DNT), Metabolic Regulators (DI HEPTARINE S, DYSANTIC), Probiotics (FLORAMAX B-11, ZYMOSPORE), Mycotoxin Control (INACTIVATOR/DETOXA PLUS, Detoxa Book publications), Anticoccidials (LONOMICIN D, VETRIBAC), Feed Additives (HERBANOPLEX CP, UNIWALL MOS, GAMAXINE), and Digital Tools (VETANCID APP, VIIP Intestinal Integrity Program). The company also produces injectables (MICROFLUD CEFT) and disinfectants (VETANCID). Products cover poultry, swine, cattle, and pet segments. Vetanco operates through the BV Science joint venture with Dr. Bata Ltd. and the Bioinnovo partnership with INTA for vaccine development.

Differentiator

Problem solved

Functional benefit

Brands

• BV Science: Joint business unit between Vetanco S.A. and Dr. Bata Ltd., focused on research and development of antibiotic-free solutions for animal production, operating across the Americas, Europe, and Asia.
• Bioinnovo

Products and services

• vedevax BLOCK First recombinant subunit vaccine against Bovine Viral Diarrhea (BVD) virus, developed by Bioinnovo (INTA and Vetanco joint venture). Uses baculovirus and targeting E2 glycoprotein to immune system cells, providing protection for at least 12 months based on antibody titer studies. Safe for pregnant females and all animal categories. Sold to commercial beef and dairy cattle operations.
• Bioinnovo IgY DNT First biological product for prevention and treatment of neonatal calf diarrhea, developed by Bioinnovo (Vetanco and INTA joint venture). Neutralizes two viruses in the gastrointestinal tract using IgY antibody technology. Sold to cattle producers including dairy farms.
• BIOTECH VAC SALMONELLA

Quantifiable outcome

• vedevax BLOCK provides protection for at least 12 months based on antibody titer studies in cattle
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core, strategic and minor.

• Dr. Bata Ltd. (Hungary)coreStrategic or Co-development Partner · 1 January 2016Strategic partnership formed in 2016 combining Vetanco's Latin American market presence with Dr. Bata's European R&D capabilities. The partnership merged research, marketing, and technical support departments to create BV Science joint business unit operating in the Americas, Europe, and Asia. In 2017, established BV Science Inc. subsidiary in St. Louis, USA. Dr. Bata announced construction of first factory in Brazil in 2022.
• INTA (Instituto Nacional de Tecnología Agropecuaria) - ArgentinacoreStrategic or Co-development PartnerPublic-private partnership with Argentina's National Agricultural Technology Institute. Created Bioinnovo S.A., a Technology-Based Company (EBT) for joint development of biotechnology products including IgY antibodies and recombinant vaccines. INCUINTA platform manages technology projects transferred to Bioinnovo for commercialization. Partnership produced vedevax BLOCK (first recombinant BVDV vaccine) and Bioinnovo IgY DNT (neonatal calf diarrhea treatment).
• Bioinnovo S.A.coreStrategic or Co-development PartnerJoint venture between Vetanco and INTA for biotechnology product development and commercialization. Launched first product Bioinnovo IgY DNT in 2017 for neonatal calf diarrhea. Second product vedevax BLOCK launched for BVDV prevention. Research spanning more than a decade with 4+ years of scale-up and registration through IncuINTA before commercialization.
• BV Science (Joint Business Unit)coreStrategic or Co-development PartnerJoint business unit formed by Vetanco S.A. and Dr. Bata Ltd. combining their research, marketing, and technical support operations. Coordinates activities across the Americas, Europe, and Asia. Established US subsidiary BV Science Inc. in St. Louis in late 2017. Participated in IPPE annually since 2016 with commercial booth and scientific forum presentations.
• Arasco/Al-Emar Internacional - Saudi ArabiastrategicChannel Partner/ Reseller/ DistributorStrategic alliance with Al-Emar Internacional, Arasco's animal health business unit, to enhance animal health in the Middle East region. Vetanco formalized the partnership to expand presence in Middle Eastern markets.
• Nada Al Arabia Trading Est. - Saudi ArabiaminorChannel Partner/ Reseller/ DistributorDistribution partner in Saudi Arabia covering Riyadh region with marketing and sales support.
• Fundación Empujar - ArgentinaminorOthersSocial responsibility partnership hosting job training programs for youth at Vetanco's General Rodríguez plant. Part of CSR initiative with Unión Industrial de General Rodríguez.
• Hospital Garrahan - ArgentinaminorOthersCSR partnership where Vetanco recycles waste materials transformed into donations for Hospital Garrahan pediatric hospital.
• Unión Industrial de General Rodríguez - ArgentinaminorOthersPartnership with local industrial association for CSR programs including women entrepreneurs initiatives, job training, and interview simulations.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Virbac: Virbac is a France-based global veterinary pharmaceutical company offering pharmaceuticals, vaccines, and feed additives across companion and production animals. Comparable product breadth and global subsidiary structure, though larger in scale.
• Vetoquinol: Vetoquinol is a French veterinary pharmaceutical company serving companion animals and livestock with a similar mix of pharmaceuticals, biologicals, and feed-related specialties. Comparable in size and multi-region strategy to Vetanco.
• Ceva Santé Animale: Ceva is a global veterinary pharmaceutical and biologics company with a strong vaccine portfolio (poultry, swine, ruminants) and a meaningful presence in Latin America. Comparable as a multi-species animal health manufacturer with emphasis on biologicals and a comparable international subsidiary footprint.
• Phibro Animal Health: Phibro Animal Health is a publicly traded animal health and nutrition company offering vaccines, antibacterials, and feed additives for poultry, swine, and cattle. Closely comparable to Vetanco across species focus, product mix (including antibiotic and nutritional specialty lines), and production-animal customer base.
• Hipra: Hipra is a Spanish veterinary biologics specialist focused on vaccines for livestock (notably BVD and other ruminant vaccines). Directly comparable to Vetanco's Bioinnovo/BV Science biologics pipeline and Cattle segment, particularly around BVDV vaccination where Vedevax BLOCK competes.

Broad incumbents

• Elanco Animal Health: Elanco is a global top-tier animal health company with extensive poultry, swine, and cattle product lines including vaccines, parasiticides, and feed additives. Comparable in therapeutic areas served but materially larger and broader than Vetanco.
• Zoetis: Zoetis is the world's largest animal health company with comprehensive pharmaceutical, vaccine, diagnostic, and genetic test portfolios across all major livestock species. Comparable in therapeutic areas but vastly larger in scale, R&D budget, and global reach.

Emerging players

• Kemin Industries: Kemin is a global ingredient manufacturer with significant animal nutrition and feed additive offerings, including mycotoxin management. Comparable to Vetanco's feed additives and mycotoxin control product lines (Detoxa Plus, Inactivator, Herbanoplex CP).

Regional players

• Ourofino Saúde Animal: Ourofino is a Brazilian veterinary pharmaceutical and biological company with a strong LatAm focus on livestock (cattle, poultry, swine) and companion animals. Comparable in geographic focus and product mix but primarily Brazilian-market.

Others

• Dr. Bata Ltd. Dr. Bata is a Hungarian veterinary pharmaceutical company and Vetanco's JV partner in BV Science. Listed separately because it is simultaneously a partner and a comparable peer in terms of product portfolio (antibiotic-free animal production, livestock pharmaceuticals), making it a useful adjacent benchmark for Vetanco's growth pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/vetancouruguay
• Xx.com/vetancomexico
• Facebookfacebook.com/vetancoargentina

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetanco